Research Studies

The Beyond Study

Apretude is the first and only long-acting injectable HIV prevention medication (PrEP) given once every other month via intramuscular injection. Apretude is a brand name version of extended release cabotegravir. It is FDA approved for people who are HIV negative and want to reduce their risk of contracting HIV.

The Beyond Study is a research study administered by Bridge HIV in partnership with Lyon-Martin Community Health Services with the aim of increasing access to Apretude for Transgender and Non-Binary people. The study is for Transgender and Non-Binary People who are HIV negative, over the age of 18, and want to try Apretude to reduce the risk of contracting HIV.

If you are interested in joining The Beyond Study, contact
Positive Care Coordinator, Bo Hwang, at (415) 213-1919 or